Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2018. Ca Cancer J Clin. 2018; https://doi.org/10.3322/caac.21442.

RCOG Green-top guideline No. 12. Pregnancy and breast cancer. Royal College of Obstetricians and Gynaecologists; 2011.

Google Scholar 

Suelmann BBM, van Dooijeweert C, van der Wall E, Linn S, can Diest PJ. Prencnay-associated breast cancer: nationwide Dutch study confirms discriminatory aggressive histopathology profile. Breast Cancer Res Treat. 2021; https://doi.org/10.1007/s10549-021-06130-w.

Ruiz R, Herrero C, Strasser-Weippl K, Touya D, St Louis K, et al. Epidemiology and pathophysiology of pregnancy-associated breast cancer: a review. Breast. 2017; https://doi.org/10.1916/j.breast2017.008.

Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers. Int J Cancer. 2005; https://doi.org/10.1992/ijc.21273.

Yu JH, Kim MJ, Cho H, Liu HJ, et al. Breast diseases during pregnancy and lactation. Obstet Gynecol Sci. 2013;56:143–59.

Article  PubMed  PubMed Central  Google Scholar 

Soto-Trujillo D, Santos Aragón LN, Kimura Y. Pregnancy-associated breast cancer: what radiologists must know. Cureus. 2020;12(9):e10343. https://doi.org/10.7759/cureus.10343. Findings in this study corroborated ultrasound as imaging modality of choice in PABC, with reported sensitivity of up to 100% with negative predictive value of up to 100%. Mammography should be pursued if clinical suspicion persists. There is limited role for breast MRI; imaging modalities employing radiation should be avoided.

Article  PubMed  PubMed Central  Google Scholar 

Robbins J, Jeffries D, Roubidoux M, Helvie M. Am J Roentgenol. 2011;196:716–22.

Article  Google Scholar 

Vashi R, Hooley R, Butler R, Geisel J, et al. Breast imaging of the pregnant and lactating patient: physiologic changes and common benign entities. AJR Am J Roentgenol. 2013;200:329–36.

Article  PubMed  Google Scholar 

Oh KY, Roberts VH, Schabel MC, Grove KL, et al. Gadolinium chelate contrast material in pregnancy: fetal biodistribution in the nonhuman primate. Radiology. 2015;276(1):110–8. https://doi.org/10.1148/radiol.15141488.

Article  PubMed  Google Scholar 

Mühler MR, Clément O, Salomon LJ, Balvay D, et al. Maternofetal pharmacokinetics of a gadolinium chelate contrast agent in mice. Radiology. 2011;258(2):455–60. https://doi.org/10.1148/radiol.10100652.

Article  PubMed  Google Scholar 

De Santis M, Straface G, Cavaliere AF, Carducci B, et al. Gadolinium periconceptional exposure: pregnancy and neonatal outcome. Acta Obstet Gynecol Scand. 2007;86(1):99–101.

Article  PubMed  Google Scholar 

ACR manual on contrast media (version 2023). Am Col of Rad 2022; https://www.acr.org/Clinical-Resources/Contrast-Manual. Accessed 7 Apr 2023

Shachar SS, Gallagher K, McGuire K, Zagar TM, et al. Multidisciplinary management of breast cancer during pregnancy. Oncologist. 2017;22(3):324–34. https://doi.org/10.1634/theoncologist.2016-0208.

Article  PubMed  PubMed Central  Google Scholar 

Fisher B, Anderson S, Bryant J, Margolese RG, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.

Article  PubMed  Google Scholar 

Rosen MA. Management of anesthesia for the pregnant surgical patient. Anesthesiology. 1999;91:1159–63.

Article  CAS  PubMed  Google Scholar 

Network NCC. Breast Cancer Version (4. 2023), 2023. Available online: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 Apr 2023

Toesca A, Gentilini O, Peccatori F, Azim HA, et al. Locoregional treatment of breast cancer during pregnancy. Gynecol Surg. 2014;11(4):279–84.

Article  PubMed  PubMed Central  Google Scholar 

Donker M, van Tienhoven G, Straver ME, Meijnen P, et al. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicenter, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–10. https://doi.org/10.1016/S1470-2045(14)70460-7.

Article  PubMed  PubMed Central  Google Scholar 

Lohsiriwat V, Peccatori FA, Martella S, Azim HA, et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast. 2013;22(5):657–60. https://doi.org/10.1016/j.breast.2013.06.005.

Article  PubMed  Google Scholar 

Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg. 2003; https://doi.org/10.1001/archsurg.138.1.91.

Amant F, Vandenbroucke T, Verheecke M, Fumagalli M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015; https://doi.org/10.1056/NEJMoa1508913.

Ring AE, Smith IE, Jones A, Shannon C, et al. Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. J Clin Oncol. 2005; https://doi.org/10.1200/JCO.2005.03.038.

Amant F, Nekljudova V, Maggen C, Seither F, et al. Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls. Eur J Cancer. 2022; https://doi.org/10.1016/j.ejca.2022.04.014. This large, multi-center retrospective study compared survival of patients with PABC treated with chemotherapy versus non-pregnant patients treated with chemotherapy. At median follow-up of 66 months, DFS and OS were comparable for pregnant and non-pregnant patients.

Paris I, Di Giorgio DD, Carbognin L, Corrado G. Pregnancy-associated breast cancer: a multidisciplinary approach. Clin Breast Cancer. 2020; https://doi.org/10.1016/j.clbc.2020.07.007.

Azim HA Jr, Mastro LD, Scarfone G, Peccatori FA. Treatment of breast cancer during pregnancy: regimen selection, pregnancy monitoring and more. Breast. 2011; https://doi.org/10.1016/j.breast/2010.10.008.

Hahn KM, Johnson PH, Gordon N, Kuerer H, et al. Treatment of pregnant breast cancer patients and outcome of children exposed to chemotherapy in utero. Cancer. 2006; https://doi.org/10.1002/cncr.22081.

Peccatori FA, Azim HA Jr, Scarfone G, Gadducci A, et al. Weekly epirubicin in the treatment of gestational breast cancer (GBC). Breast Cancer Res Treat. 2009; https://doi.org/10.1007/s10549-008-0159-2.

Cardonick E, Dougherty R, Grana G, Gilmandyar D, Ghaffar S, et al. Breast cancer during pregnancy: maternal and fetal outcomes. Cancer J. 2010; https://doi.org/10.1097/ppo.0b013e3181ce46f9.

Poggio F, Tagliamento M, Pirrone C, Soldato D, et al. Update on management of breast cancer during pregnancy. Cancers (Basel). 2020; https://doi.org/10.3390/cancers12123616.

Mir O, Berveiller P, Goffient F, Treluyer JM, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol. 2010; https://doi.org/10.1093/annonc/mdp517.

Zagouri F, Sergentanis TN, Chrysikos D, Dimitrakakis C, et al. Taxanes for breast cancer during pregnancy: a systematic review. Clinical Breast Cancer. https://doi.org/10.1016/j.clbc.2012.09.014.

Safi N, Anazodo A, Dickinson JE, Lui K, et al. In utero exposure to breast cancer treatment: a population-based perinatal outcome study. Br J Cancer. 2019; https://doi.org/10.1038/s41416-019-0563-x.

O’Laughlin ABS, So S, Fleischer L, Akoto S, et al. Safety of taxane chemotherapy in breast cancer during pregnancy. Obst Gynecol. 2019; https://doi.org/10.1097/01.AOG.0000558888.89911.f0.

Tehrani OS. Systemic treatments in pregnancy-associated breast cancer. In: Alipour S, Omranipour R, editors. Diseases of the breast during pregnancy and lactation. Advances in Experimental Medicine and Biology, vol. 1252. Cham: Springer. https://doi.org/10.1007/978-3-030-41596-9_15.

Corona-Rivera JR, Rea-Rosas A, Santana-Ramírez A, Acosta-León J, et al. Holoprosencephaly and genitourinary anomalies in fetal methotrexate syndrome. Am J Med Genet. 2010; https://doi.org/10.1002/ajmg.a.33496.

Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012; https://doi.org/10.1097/aog.0b013e31826c32d9.

Trastuzumab intravenous injection. United States Prescribing Information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103792s5256lbl.pdf (Accessed on March 25, 2023).

Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, et al. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013; https://doi.org/10.1007/s10549-012-2368-y.

Lambertini M, Martel S, Campbell C, Guillaume S, et al. Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials. Cancer. 2019; https://doi.org/10.1002/cncr.31784.

Schuurman TN, Witteveen PO, van der Wall E, Passier JLM, et al. Tamoxifen and pregnancy: an absolute contraindication? Breast Cancer Res Treat. 2019; https://doi.org/10.1007/s10549-019-05154-7.

Schmid P, Javier C, Pusztai L, McArthur H, et al. Pembrolizumab for early triple-negative breast cancer. New Engl. J Med. 2020; https://doi.org/10.1056/NEJMMoa1910549.

Finn RS, Martin M, Rugo HS, Jones S, et al. Palbociclib and letrozole in advanced breast cancer. New Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1607303.

Hortobagyi GN, Stemmer SM, Burris HA, Ys Y, et al. Ribociclib as first-line therapy for HR-positive advanced breast cancer. New Engl J Med. 2016; https://doi.org/10.1056/NEJMoa1609709.

Sledge GW, Toi M, Neven P, Sohn J, et al. Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017; https://doi.org/10.1200/JCO.2017.73.7585.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development. Available from: https://www.ncbi.nlm.nih.gov/books/NBK500944. Accessed 31 Mar 2023

Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021; https://doi.org/10.1007/s11523-021-00796-4.

Spring L, Niemierko A, Haddad S, et al. Effectiveness and tolerability of neoadjuvant pertuzuamb-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat. 2018; https://doi.org/10.1007/s10549-018-4959-8.